California Stem Cell Submits Phase II Clinical Trial Protocol to FDA for Treating Ovarian Cancer

California Stem Cell, Inc. announced today it has submitted a Phase II protocol to the U.S. Food and Drug Administration for a randomized, double-blind study to evaluate CSC's patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

http://ift.tt/KN2ezw